The ACE/DD–ACE/ID polymorphism was able to predict the response to losartan in type 2 diabetic patients enrolled in the RENAAL trial, that is, patients with worse prognosis (D allele carriers) had the best response to losartan [111]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.